On March 4, 2025, Scienture Holdings Inc. entered into a 10-year exclusive agreement with Kindeva to commercialize a nasal spray product, with potential milestone payments between $2.5 million and $10 million based on sales targets, and a profit-sharing model of 10% of net sales.